Sugi Predict

Sugi Predict / Compounds / SCHEMBL1947532

SCHEMBL1947532

SCHEMBL1947532

c1cncc(-c2cnc3sc(NCc4cccs4)nn23)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
▸ FYN P06241 16/20 1.00
▸ CYP1A2 P05177 3/20 0.52
▸ CYP3A4 P08684 3/20 0.52
▸ CYP2D6 P10635 3/20 0.52
▸ ALOX15 P16050 2/20 0.52
▸ HSD17B10 Q99714 2/20 0.52
▸ CLK4 Q9HAZ1 2/20 0.52
▸ MEN1 O00255 2/20 0.52
▸ KMT2A Q03164 2/20 0.52
▸ ALDH1A1 P00352 1/20 0.52
▸ CYP2C9 P11712 1/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ CYP2C19 P33261 1/20 0.52
▸ MKNK1 Q9BUB5 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1946215 0.90 FYN (1.00) FYNMKNK1
SCHEMBL1944815 0.89 FYN (0.84) FYNMKNK1
SCHEMBL1945032 0.85 FYN (0.87) FYNMKNK1
SCHEMBL1945138 0.83 FYN (0.79) FYNMKNK1
SCHEMBL1944437 0.83 FYN (1.00) FYNALDH1A1MKNK1
SCHEMBL1945522 0.83 FYN (0.71) FYN
SCHEMBL1945528 0.82 FYN (0.78) FYNMKNK1
SCHEMBL1944698 0.82 FYN (0.71) FYN
SCHEMBL1946088 0.81 FYN (1.00) FYN
SCHEMBL30521654 0.81 FYN (1.00) FYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180250297-A1 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors Pathways Neuro Pharma, Inc. 2018-09-06 — — US claimed
EP-3347462-A1 METHODS, COMPOSITIONS, AND USES OF NOVEL FYN KINASE INHIBITORS Lau, Warren C. (US) 2018-07-18 — — EP claimed
WO-2017044623-A1 METHODS, COMPOSITIONS, AND USES OF NOVEL FYN KINASE INHIBITORS LAU WARREN C (US) 2017-03-16 — — WO claimed
EP-2307425-B1 IMIDAZOTHIADIAZOLES DERIVATIVES MERCK PATENT GMBH (DE) 2014-03-26 — — EP claimed
US-20240041868-A1 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors Pathways Neuro Pharma, Inc. 2024-02-08 — — US disclosed
US-11701353-B2 Methods, compositions, and uses of novel FYN kinase inhibitors Pathways Neuro Pharma, Inc. (US) 2023-07-18 — — US disclosed
US-11701353-B2 Methods, compositions, and uses of novel FYN kinase inhibitors Pathways Neuro Pharma, Inc. (US) 2023-07-18 — — US disclosed
US-11701353-B2 Methods, compositions, and uses of novel FYN kinase inhibitors Pathways Neuro Pharma, Inc. (US) 2023-07-18 — — US disclosed
US-20210030753-A1 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors Pathways Neuro Pharma, Inc. 2021-02-04 — — US disclosed
US-10688093-B2 Methods, compositions, and uses of novel Fyn kinase inhibitors Pathways Neuro Pharma, Inc. 2020-06-23 — — US disclosed
US-10688093-B2 Methods, compositions, and uses of novel Fyn kinase inhibitors Pathways Neuro Pharma, Inc. 2020-06-23 — — US disclosed
US-20180250297-A1 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors Pathways Neuro Pharma, Inc. 2018-09-06 — — US disclosed
EP-2307425-B1 IMIDAZOTHIADIAZOLES DERIVATIVES MERCK PATENT GMBH (DE) 2014-03-26 — — EP disclosed
US-8389554-B2 Imidazothiadiazole derivatives MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2013-03-05 — — US disclosed
US-8389554-B2 Imidazothiadiazole derivatives MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2013-03-05 — — US disclosed
US-8389554-B2 Imidazothiadiazole derivatives MERCK Patent Gesellschaft mit beschränkter Haftung (DE) 2013-03-05 — — US disclosed
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-06-02 — — US disclosed
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-06-02 — — US disclosed
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2011-06-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240041868-A1 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors FYN, LCK, PTK2B FYN 1/4885CYP1A2 3936/4885CYP3A4 4445/4885
US-20180250297-A1 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors FYN, LCK, PTK2B FYN 1/4885CYP1A2 3936/4885CYP3A4 4445/4885
US-11701353-B2 Methods, compositions, and uses of novel FYN kinase inhibitors FYN, LCK, PTK2B FYN 1/4885CYP1A2 3936/4885CYP3A4 4445/4885
US-20110130396-A1 IMIDAZOTHIADIAZOLE DERIVATIVES TGFBR1, TGFBR2, IGF1R FYN 1977/4885CYP1A2 1141/4885CYP3A4 1421/4885
US-10688093-B2 Methods, compositions, and uses of novel Fyn kinase inhibitors FYN, LCK, PTK2B FYN 1/4885CYP1A2 3936/4885CYP3A4 4445/4885
US-20210030753-A1 Methods, Compositions, and Uses of Novel FYN Kinase Inhibitors FYN, LCK, PTK2B FYN 1/4885CYP1A2 3936/4885CYP3A4 4445/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.